Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited has achieved a significant milestone with the FDA’s 510(k) clearance of its Salix® Coronary Plaque module, enhancing its commercial prospects in the U.S. market. This clearance allows Artrya to charge fees for each scan assessed, with a reimbursement rate of US$950 per assessment, and integrates seamlessly with its existing Salix® Coronary Anatomy platform. The module’s ability to provide rapid, point-of-care assessments of coronary artery plaque positions Artrya to capitalize on the growing demand for cardiac CT scans. The company is also collaborating with major U.S. hospital centers to further promote the clinical utility of its technology, aiming to transition these centers into commercial customers.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.87 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is a medical technology company that specializes in AI-powered solutions for the assessment and management of coronary artery disease. The company’s primary product, the Salix® platform, offers near real-time, point-of-care detection of coronary artery plaque, which is a significant predictor of heart attacks. Artrya is focused on expanding its market presence in the United States, where coronary artery disease is a leading cause of death and a major healthcare expenditure.
Average Trading Volume: 266,373
Technical Sentiment Signal: Buy
For an in-depth examination of AYA stock, go to TipRanks’ Overview page.